Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix in Non-Metastatic Hormone-Refractory Prostate Cancer
NCT01545882Phase 2Terminated
- Sponsor
- Ottawa Hospital Research Institute
- Start
- May 2011
- Primary completion
- Oct 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of degarelix in prostate cancer (PCa), sponsored by Ottawa Hospital Research Institute. Started May 2011; status: terminated.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01545882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545882.